CD8A and neoplasm: Compared with those of Fc-treated controls, treatment with HCT-mono-mIL12 variants resulted in significant increases in the populations of CD8+ and CD4+ TILs (Figure 3C) and their percentages expressing Ki-67, a proliferation marker, in tumor sites (Figure 3D).